Hummingbird Bioscience raises $125M to expand capabilities

Hummingbird Bioscience, an innovative clinicalstage biotech startup based in Singapore focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, has announced the closing of a $125 million Series C financing round. The financing was led by Novo Holdings, with significant participation from new investors including Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge

Group and Altrium Capital Management. Existing investors including SK

Inc, Heritas Capital, and Mirae Asset Venture

Capital also joined the round. Proceeds from the financing will be used to advance the clinical development of Hummingbird’s lead assets including, HMBD-001, a best-in-class HER3 antibody for NRG1fusion and HER3-driven tumours, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumours. The funds will also be used to expand the capabilities of Hummingbird’s proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics including HMBD-009, a BCMA-TACI dualspecific T cell engager.